Latest news

• Amgen raises forecasts after closing $13.4bn Otezla deal

  Otezla slots into Amgen’s existing psoriasis and anti-inflammatory product range, which includes Enbrel (etanercept) and Amgevita, its biosimilar of AbbVie’s Humira (adalimumab) which is approved and already available

• UPDATED: BMS completes Celgene merger after FTC okay

  Otezla slots nicely into Amgen’s existing psoriasis and anti-inflammatory portfolio, which includes TNF inhibitor Enbrel (etanercept) and Amgevita, its biosimilar of AbbVie’s top-selling TNF blocker Humira (adalimumab). ... Amgevita is approved and

• Amgen snaps up Celgene’s Otezla for $13.4bn

  This includes Enbrel (boosted earlier this month by a successful defence of its US patent) and Amgevita, its Humira biosimilar, which is approved and already available in Europe and approved ahead

• Generic Differentiation

  is doing with Amgevita.

• NHS says Humira biosimilar deal will save £300m

  end. Amgen’s copy Amgevita and Samsung and Biogen’s Imraldi both gained full EU approval last year, and have been joined since by Hyrimoz from Novartis’ Sandoz division, Boehringer